JVJelle Vehof

Jelle Vehof

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jelle Vehof has a total of 137 co-authors. Here are the top co-authors by number of shared publications:

  • Morten Schjerven Magno

    Department of Plastic and Reconstructive Surgery Oslo University Hospital Oslo Norway

    15 shared publications
  • Tor P. Utheim

    Department of Ophthalmology, Sørlandet Hospital Arendal, Arendal, Norway; Department of Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway; Department of Ophthalmology, Faculty of Life Course Sciences and Medicine, King's College London, London, United Kingdom

    13 shared publications
  • Christopher J. Hammond

    Department of Twin Research and Genetic Epidemiology, King’s College London, London, UK

    10 shared publications
  • Christopher J. Hammond

    Department of Twin Research & Genetic Epidemiology, King's College London, St Thomas' Hospital, London, United Kingdom; Department of Ophthalmology, King's College London, St Thomas' Hospital, London, United Kingdom; Department of Ophthalmology, Sørlandet Hospital Arendal, Norway

    8 shared publications
  • Harold Snieder

    Department of Epidemiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Postbus 30.001, Groningen, the Netherlands

    6 shared publications
  • Emily Moschowits

    Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway

    5 shared publications

Latest Publications

  • Open Access

    Does lacrimal gland ultrasound discriminate between Sjögren’s disease and non-Sjögren’s sicca patients?

    by Nrf Sluijpers, T Yang, Aj Stel, Jf van Nimwegen, L Olie, J Vehof, Ksm van der Geest, H Bootsma, S Arends, A Coumou, et al.

    Sjögren’s disease (SjD) is a chronic autoimmune rheumatic disorder, with a female-to-male ratio of approximately 9 to 1 (1). The primary targets of SjD are the exocrine glands, particularly the sal...

  • Open Access

    The association between personality and dry eye disease: A large cross-sectional study

    by Morten S. Magno, Laura E. Wolpert, Mathias K. Morthen, Tor P. Utheim, Christopher J. Hammond, Jelle Vehof


  • Open Access

    A large hypothesis-free proteomics study investigating serum inflammatory markers as biomarkers of dry eye disease

    by Jelle Vehof, Amber Rhee, Niccolò Rossi, Mario Falchi, Christopher J. Hammond, Frances M.K. Williams


  • Open Access

    Quantitative sensory testing and chronic pain syndromes: a cross-sectional study from TwinsUK

    by Amber Rhee, Isabelle Granville Smith, Roger Compte, Jelle Vehof, Ayrun Nessa, Samuel Wadge, Maxim B Freidin, David L Bennett, Frances M K Williams

    Objective The chronic pain syndromes (CPS) include syndromes such as chronic widespread pain (CWP), dry eye disease (DED) and irritable bowel syndrome (IBS). Highly prevalent and lacking pathognomonic biomarkers, the CPS are known to cluster in individuals in part due to their genetic overlap, but patient diagnosis can be difficult. The success of quantitative sensory testing (QST) and inflammatory biomarkers as phenotyping tools in conditions such as painful neuropathies warrant their investigation in CPS. We aimed to examine whether individual QST modalities and candidate inflammatory markers were associated with CWP, DED or IBS in a large, highly phenotyped population sample. Design Cross-sectional study. Setting Community-dwelling cohort. Participants Twins from the TwinsUK cohort Primary and secondary outcome measures We compared 10 QST modalities, measured in participants with and without a CWP diagnosis between 2007 and 2012. We investigated whether inflammatory markers measured by Olink were associated with CWP, including interleukin-6 (IL-6), IL-8, IL-10, monocyte chemoattractant protein-1 and tumour necrosis factor. All analyses were repeated in DED and IBS with correction for multiple testing. Results In N=3022 twins (95.8% women), no association was identified between individual QST modalities and CPS diagnoses (CWP, DED and IBS). Analyses of candidate inflammatory marker levels and CPS diagnoses in n=1368 twins also failed to meet statistical significance. Conclusion Our findings in a large population cohort suggest a lack of true association between singular QST modalities or candidate inflammatory markers and CPS.


  • Open Access

    Review of Hydroxypropyl Methylcellulose in Artificial Tears for the Treatment of Dry Eye Disease

    by O. Martin B. Mysen, Leif Hynnekleiv, Morten S. Magnø, Jelle Vehof, Tor P. Utheim

    Dry eye disease (DED) is a highly prevalent condition, resulting in reduced quality of life, lower participation in social life and impaired work efficiency. Hydroxypropyl methylcellulose (HPMC) is a cellulose‐based viscosity‐enhancing agent and is one of the most popular therapeutic ingredients in artificial tears. This review aims to evaluate the literature on the efficacy and safety of HPMC used in the treatment of DED. Literature searches were conducted in PubMed and Cochrane CENTRAL. A total of 28 clinical trials from 26 publications are included in this review, including 21 clinical intervention studies evaluating the effect of HPMC treatment over time and seven single instillation studies evaluating the short‐term physical and symptomatic effects of HPMC after drop‐instillation. The duration of clinical intervention studies ranged from 2 weeks to 5.5 months. DED severity ranged from mild to severe. Drop frequency ranged from two to up to 16 drops per day. HPMC concentration in artificial tears ranged from 0.2% to 0.5%. No major complications or adverse events were reported. Artificial tears containing HPMC were effective at improving symptoms and some signs of DED. However, combination drops with HPMC plus other therapeutic ingredients seem more effective than HPMC alone. HPMC appears to be equally effective or inferior to hyaluronic acid (HA). There is no evidence of superiority or inferiority to either carboxymethylcellulose (CMC) or polyethylene glycol 400/propylene glycol (PEG/PG). No single study explained the choice of drop frequency or HPMC concentration. More well‐designed studies are needed to determine an evidence‐based standard for HPMC treatment, including drop frequency, concentration and molecular weight for different DED severity and subgroups.


  • Open Access

    Topical glaucoma medications − Possible implications on the meibomian glands

    by Fredrik Fineide, Morten Magnø, Kristian Dahlø, Miriam Kolko, Steffen Heegaard, Jelle Vehof, Tor Paaske Utheim

    One of the most common causes of blindness on a global scale is glaucoma. There is a strong association between glaucoma and increased intraocular pressure (IOP). Because of this, adequate IOP‐lowering is the most important treatment strategy, mostly through topical eyedrops. Well‐functioning meibomian glands are paramount for maintaining a stable tear film, and their dysfunction is the most common cause of dry eye disease. There is a growing concern that both topical glaucoma medications themselves and their added preservatives damage the meibomian glands, and consequently, the ocular surface. Preserved topical glaucoma medications appear to cause dysfunction and atrophy of the meibomian glands. Upon comparison, preserved formulations caused more symptoms of dry eye, tear film instability, inflammatory changes and meibomian gland dropout than the preservative‐free counterpart. However, although seemingly less detrimental, unpreserved alternatives may diminish glandular efficacy, and, depending on the active ingredient, lead to glandular death. This negatively impacts quality of life, adherence to treatment regimens and prognosis. In this review, we explore the available evidence regarding the effects of IOP‐lowering eye drops on the meibomian glands.


  • Open Access

    Tear and Saliva Metabolomics in Evaporative Dry Eye Disease in Females

    by Fredrik A. Fineide, Behzod Tashbayev, Katja B. P. Elgstøen, Elise M. Sandås, Helge Rootwelt, Håvard Hynne, Xiangjun Chen, Sten Ræder, Jelle Vehof, Darlene Dartt, et al.

    Accurate diagnosis of dry eye disease (DED) is challenging, and even today there is no gold standard biomarker of DED. Hypothesis-free global metabolomic studies of tears from DED patients have great potential to discover metabolites and pathways affected in the pathophysiology of DED, and to identify possible future biomarkers. These metabolites and biomarkers could be important for diagnosing and monitoring disease as well as for new therapeutic targets and strategies. As DED is associated with dry mouth, this study aimed to perform metabolomic analyses of tears and saliva from patients with decreased tear film break-up time but normal Schirmer test, and age-matched controls with both tear production and stability within physiological range. We applied strict inclusion criteria to reduce sampling bias in the metabolomic analyses and selected only age-matched females with Schirmer test values between 10–15 mm/5 min. The tear film analysis arm included 19 patients (with tear film break-up time 0–5 s) and 12 controls (with tear film break-up time 10–30 s), while the salivary analysis arm consisted of a subset which included 18 patients and six controls. Metabolomic analyses were performed using liquid chromatography and high-resolution mass spectrometry. Analyses using a global database search detected a total of 56 metabolites in tear samples that were significantly different between the groups. Of these, several have known associations with DED. These metabolites are present in meibum and have anti-oxidative characteristics or associations with the ocular microbiome, and altered concentrations suggest that they may play a significant role in DED associated with decreased tear film stability. In saliva, hypotaurine levels were lower among patients with tear film instability. In this pilot study, we found different levels of several metabolites in patients with decreased tear film break-up time that may have associations with DED. Future studies are required to replicate our findings and clarify the exact roles of these metabolites.


  • Open Access

    Greater adherence to a mediterranean diet is associated with lower C-reactive protein (CRP) levels, but not to lower odds of having dry eye disease

    by Morten Schjerven Magno, Emily Moschowits, Mathias Kaurstad Morthen, Marie Wangen Beining, Nomdo M. Jansonius, Christopher J. Hammond, Tor P. Utheim, Jelle Vehof


  • Open Access

    Intense pulsed light treatment in meibomian gland dysfunction: Past, present, and future

    by Fredrik Fineide, Morten S. Magnø, Ayyad Zartasht Khan, Xiangjun Chen, Jelle Vehof, Tor P. Utheim

    Dry eye disease is a highly prevalent condition, which can substantially impair quality of life, work productivity, and vision. It is considered an inflammatory disease and the most common cause is meibomian gland dysfunction. Despite many treatment alternatives being available, including artificial tears, warm compresses, antibiotics, and anti‐inflammatory therapy, lasting treatment effects are rare. Over the last two decades, intense pulsed light therapy, after being well established in dermatology, has been gradually introduced to the field of ophthalmology to treat meibomian gland dysfunction. The purpose of the current article is to critically review the clinical studies assessing the use of intense pulsed light to treat meibomian gland dysfunction published to date. The vast majority of the included studies demonstrated improved symptoms and signs, although the degree of efficacy and its duration varied greatly depending on concomitant treatment, number of treatment sessions, and other factors. Several possible mechanisms of action concerning disease propagation and treatment efficacy are discussed. There is still a need for larger, randomised, longitudinal studies to define the most efficacious treatment regime and to predict which patients may benefit the most. More studies are needed on implementing biochemical analyses and machine learning algorithms. Such studies may prove beneficial in predicting treatment effects, defining optimal treatment regimens, and furthering our understanding of the mechanisms of action.


  • Open Access

    A comparison between hyaluronic acid and other single ingredient eye drops for dry eye, a review

    by Leif Hynnekleiv, Morten Magno, Emily Moschowits, Kim Alexander Tønseth, Jelle Vehof, Tor P. Utheim

    Dry eye disease (DED) is a highly prevalent and debilitating condition. Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan that has a long history as a safe and effective DED treatment. HA is frequently used as a comparator when assessing other topical DED treatments. This study aims to summarise and critically evaluate the literature describing all isolated active ingredients that have been directly compared with HA in the treatment of DED. A literature search was conducted in Embase using Ovid on the 24th of August 2021 and in PubMed including MEDLINE on the 20th of September 2021. Twenty‐three studies met the inclusion criteria, 21 of which were randomised controlled trials. Seventeen different ingredients representing six treatment categories were compared with HA treatment. Most measures showed no significant difference between treatments, suggesting either equivalency of treatments or that studies were underpowered. Only two ingredients were represented in more than two studies; carboxymethyl cellulose treatment appears equivalent to HA treatment, while Diquafosol treatment appears superior to HA treatment. Drop‐frequency varied from one to eight drops daily. No single study explained the choice of drop frequency. Nine studies used a HA concentration of 0.1% which may be below therapeutic levels. Nine studies reported using preserved formulations, six of them with differences in preservatives between the compared groups. Thirteen studies were financially linked to industry. No major complications were reported. Studies were not designed to find differences in treatment effects for different types or severities of DED. HA is a good comparator treatment when assessing other DED treatments, although consensus after decades of use is still lacking for best choice of concentration, molecular weight and drop tonicity. Well‐designed studies are needed to determine an evidence‐based standard for HA treatment to be used as comparator.